Prostate Cancer International is
for 2011 by Great NonProfits
There are new data showing that the antidepressant escitalopram (Lexapro/Forest) — a selective serotonin re-uptake inhibitor or SSRI — can significantly reduce hot flashes among women undergoing menopause. If that is the case, one wonders whether drugs of this class might have a similar impact on hot flashes in men on androgen deprivation therapy (ADT).
Filed under: Living with Prostate Cancer, Management | Tagged: hot flashes, Management, Prevention, SSRIs | 2 Comments »
At some point in the past 3 weeks or so, the National Comprehensive Cancer Network (NCCN) Foundation has quietly issued its new NCCN Guidelines for Patients™ on prostate cancer diagnosis and management.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, guidelines, Management, NCCN, patient | Leave a Comment »
The need for patients diagnosed with early stage prostate cancer to be highly involved in the decision as to which form of management they wish to be given is well understood. However, there has been a relative dearth of data on why patients actually make their individual decisions.
Filed under: Diagnosis, Management, Treatment | Tagged: choice, first line, intermediate, localized, low, Management, patient, risk, Treatment | 2 Comments »
Among prostate cancer specialists, there has been a broad acceptance — for some time — of the idea that a localized prostate cancer “index” tumor with a Gleason score of 6 or less and a volume of ≤ 0.5 cm3 could be considered to be clinically insignificant and therefore did not (necessarily) need to be treated.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: clinical insignificance, clinical significance, Gleason grade, Management, staging, tumor volume | Leave a Comment »
At the beginning of November, we commented on a re-analysis of the PLCO data by Crawford et al. — a re-analysis that focused on the impact of co-morbidities on treatment and outcomes over time.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Co-morbidity, early detection, localized, low risk, Management, screening | Leave a Comment »
A story about a 35-year-old male, newly diagnosed with prostate cancer, ran on a Houston television station yesterday.
Filed under: Diagnosis, Management, Risk | Tagged: Diagnosis, facts, Management, risk | 5 Comments »
A common topic of discussion among some members of the patient and patient advocacy community is whether recommended management of prostate cancer for individual patients is driven by the potential revenue available to physicians and hospitals from differing recommendations.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cost, low risk, Management, revenue, Treatment | 7 Comments »
WARNING: This commentary may not be suitable reading for those who are firmly convinced that annual, mass, population-based screening of all men over (say) 40 or 50 years of age is the right way to manage prostate cancer risk.
Filed under: Diagnosis, Prevention, Risk | Tagged: Management, risk, screening, testing | 20 Comments »
Most knowledgeable prostate cancer advocates and educators know that the answer to this question is “No.” The correct answer is that the management of localized prostate cancer needs to take account of the characteristics, objectives, and expectations of each individual patient, including his overall health and quality of life.
Filed under: Management, Treatment | Tagged: localized, Management, review, Treatment | 8 Comments »
Biochemical failure (also known as biochemical recurrence) after first-line treatment for prostate cancer is assessed based on a rising PSA level. This is a relatively common event and can happen shortly after first line treatment or many years later. The problem is that we really don’t know how important biochemical recurrence is in an individual [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: biochemical recurrence, comorbidity, Management, risk, survival | Leave a Comment »
It is probably fair to say that readers should expect little in the way of revolutionary new information affecting the management of prostate cancer from this year’s annual meeting of the American Urological Association (AUA). However,
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk, Treatment | Tagged: active surveillance, imaging, Management, screening | 4 Comments »
As Leah wrote in a comment on this blog just the other day, “Yes, the ‘D-word’ is still taboo. Death is UNAMERICAN.” The comment stimulated the thought that our preconceptions have significant impact on how we think about risk, diagnosis, and treatment of prostate cancer — and yet there is really very little good research on [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: decision-making, knowledge, Management, perception, Treatment | 26 Comments »
Two recent studies have examined the increasing economic burden of prostate cancer — in the USA and in selected European nations. The picture is not a pretty one.
Filed under: Diagnosis, Management, Treatment | Tagged: cost, Management | 3 Comments »
Three recent publications are focused on the importance of the management of complications of long-term androgen deprivation therapy (ADT) in men with progressive or more advanced forms of prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, Management, side effects | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site